TXN and pulmonary arterial hypertension: Furthermore, BBR (10 μmol/L) ameliorated pulmonary arterial hypertension (PAH) and vascular remodeling by inhibiting the thioredoxin (Trx)1/β-catenin pathway and inhibited hypoxia-induced pulmonary artery smooth muscle cells proliferation, providing a new target toward the pathological mechanism of PAH (Wande et al., 2020).